Chief Scientific Officer at Psychogenics Mark Varney speaks to @PharmaVoice about how their proprietary SmartCube technology will be used to analyse our MDMA-inspired drug candidates developed with UWA.

“A third of (depression) patients don’t respond at all (to existing drugs). And so those patients we define as treatment-resistant patients. Those are the patients that we would be targeting with these sorts of therapies.”

https://www.pharmavoice.com/news/MDMA-neurological-drug-development-PsychoGenics/633549/